2020
|
Sign up to set email alerts
Bilateral visual improvement with unilateral gene therapy injection for Leber hereditary optic neuropathy
Abstract: REVERSE is a randomized, double-masked, sham-controlled, multicenter, phase 3 clinical trial that evaluated the efficacy of a single intravitreal injection of rAAV2/2-ND4 in subjects with visual loss from Leber hereditary optic neuropathy (LHON). A total of 37 subjects carrying the m.11778G>A (MT-ND4) mutation and with duration of vision loss between 6 to 12 months were treated. Each subject’s right eye was randomly assigned in a 1:1 ratio to treatment with rAAV2/2-ND4 (GS010) or sham injection. The left ey… Show more
Search citation statements
Order By: Relevance
Paper Sections
Select...
198
42
31
11
Citation Types
8
261
0
0
Year Published
Range
2000
20002026
2026Publication Types
Select...
222
19
9
2
Relationship
34
218
Authors
Journals
Cited by 250 publications
(269 citation statements)
References 46 publications
8
261
0
0
Order By: Relevance
Smart CitationsHow the paper below cites the one you are viewing
“…Although this does not demonstrate an absence of vector distribution to the CNS, it is supportive of the long-term safety of lenadogene nolparvovec. These results consistent with the previously reported favorable safety profile of lenadogene nolparvovec and the absence of CNS adverse reactions [11][12][13].…”
Section: Discussion
supporting
confidence: 92%
“…Thus, this study indicates that the tumor occurrence was unrelated to lenadogene nolparvovec. These results confirm the favorable safety profile of lenadogene nolparvovec gene therapy in MT-ND4 LHON treated patients [11][12][13].…”
Section: Discussion
supporting
confidence: 79%
Absence of lenadogene nolparvovec DNA in a brain tumor biopsy from a patient in the REVERSE clinical study, a case report
BMC Neurol
Self Cite
Abstract
Smart CitationsHow the paper below cites the one you are viewing
“…Although this does not demonstrate an absence of vector distribution to the CNS, it is supportive of the long-term safety of lenadogene nolparvovec. These results consistent with the previously reported favorable safety profile of lenadogene nolparvovec and the absence of CNS adverse reactions [11][12][13].…”
Section: Discussion
supporting
confidence: 92%
“…Thus, this study indicates that the tumor occurrence was unrelated to lenadogene nolparvovec. These results confirm the favorable safety profile of lenadogene nolparvovec gene therapy in MT-ND4 LHON treated patients [11][12][13].…”
Section: Discussion
supporting
confidence: 79%
Absence of lenadogene nolparvovec DNA in a brain tumor biopsy from a patient in the REVERSE clinical study, a case report
BMC Neurol
Self Cite
Abstract
Smart CitationsHow the paper below cites the one you are viewing
“…The mean BCVA of treated subjects remained clearly on-chart, contrary to the natural history of the disease reported in MT-ND4 patients aged 15 and over at onset ( 3 ). Importantly, the continuous improvement of BCVA was reported in both eyes of unilaterally treated subjects, confirming the contralateral treatment effect of lenadogene nolparvovec reported at earlier time points in the RESCUE and REVERSE trials ( 10 , 11 ). Indeed, the absolute difference in change from baseline between drug-treated and sham-treated eyes was similar 2 and 3 years after treatment administration.…”
Section: Discussion
supporting
confidence: 79%
“…Because all MT-ND4 subjects were treated with lenadogene nolparvovec, an intrapatient comparison before and after treatment was used to assess the impact of treatment on quality of life, highlighting daily benefits experienced by each treated patient. In the overall REVERSE and RESCUE population, most of the quality-of-life metrics showed a clinically meaningful improvement from baseline to week 96, consistent with reported improvement of the visual acuity (10,11). Similarly at 3 years after treatment, this clinically meaningful improvement of most metrics was maintained, consistent with the persistence of the treatment effect of lenadogene nolparvovec on BCVA.…”
Section: Discussion
supporting
confidence: 74%
Long-Term Follow-Up After Unilateral Intravitreal Gene Therapy for Leber Hereditary Optic Neuropathy: The RESTORE Study
Journal of Neuro-Ophthalmology
Self Cite
Abstract
Smart CitationsHow the paper below cites the one you are viewing
“…Thus, we demonstrate that the iRECs can rescue the ischemic eye, restoring normal retinal vascularization. Interestingly, we found that iRECs were able to migrate to the contralateral eye, undergoing a bilateral transfer previously reported in a gene therapy study 86 . This further displays the therapeutic capabilities of the iRECs, as they can transport to ischemic regions outside the injection site to help rescue the tissue.…”
Section: Discussion
supporting
confidence: 74%
Abstract
Smart CitationsHow the paper below cites the one you are viewing
“…Although this does not demonstrate an absence of vector distribution to the CNS, it is supportive of the long-term safety of lenadogene nolparvovec. These results consistent with the previously reported favorable safety profile of lenadogene nolparvovec and the absence of CNS adverse reactions [11][12][13].…”
Section: Discussion
supporting
confidence: 92%
“…Thus, this study indicates that the tumor occurrence was unrelated to lenadogene nolparvovec. These results confirm the favorable safety profile of lenadogene nolparvovec gene therapy in MT-ND4 LHON treated patients [11][12][13].…”
Section: Discussion
supporting
confidence: 79%
Absence of lenadogene nolparvovec DNA in a brain tumor biopsy from a patient in the REVERSE clinical study, a case report
BMC Neurol
Self Cite
Abstract
Smart CitationsHow the paper below cites the one you are viewing
“…The mean BCVA of treated subjects remained clearly on-chart, contrary to the natural history of the disease reported in MT-ND4 patients aged 15 and over at onset ( 3 ). Importantly, the continuous improvement of BCVA was reported in both eyes of unilaterally treated subjects, confirming the contralateral treatment effect of lenadogene nolparvovec reported at earlier time points in the RESCUE and REVERSE trials ( 10 , 11 ). Indeed, the absolute difference in change from baseline between drug-treated and sham-treated eyes was similar 2 and 3 years after treatment administration.…”
Section: Discussion
supporting
confidence: 79%
“…Because all MT-ND4 subjects were treated with lenadogene nolparvovec, an intrapatient comparison before and after treatment was used to assess the impact of treatment on quality of life, highlighting daily benefits experienced by each treated patient. In the overall REVERSE and RESCUE population, most of the quality-of-life metrics showed a clinically meaningful improvement from baseline to week 96, consistent with reported improvement of the visual acuity (10,11). Similarly at 3 years after treatment, this clinically meaningful improvement of most metrics was maintained, consistent with the persistence of the treatment effect of lenadogene nolparvovec on BCVA.…”
Section: Discussion
supporting
confidence: 74%
Long-Term Follow-Up After Unilateral Intravitreal Gene Therapy for Leber Hereditary Optic Neuropathy: The RESTORE Study
Journal of Neuro-Ophthalmology
Self Cite
Abstract
Smart CitationsHow the paper below cites the one you are viewing
“…Thus, we demonstrate that the iRECs can rescue the ischemic eye, restoring normal retinal vascularization. Interestingly, we found that iRECs were able to migrate to the contralateral eye, undergoing a bilateral transfer previously reported in a gene therapy study 86 . This further displays the therapeutic capabilities of the iRECs, as they can transport to ischemic regions outside the injection site to help rescue the tissue.…”
Section: Discussion
supporting
confidence: 74%
Abstract
Smart CitationsHow the paper below cites the one you are viewing
“…Although this does not demonstrate an absence of vector distribution to the CNS, it is supportive of the long-term safety of lenadogene nolparvovec. These results consistent with the previously reported favorable safety profile of lenadogene nolparvovec and the absence of CNS adverse reactions [11][12][13].…”
Section: Discussion
supporting
confidence: 92%
“…Thus, this study indicates that the tumor occurrence was unrelated to lenadogene nolparvovec. These results confirm the favorable safety profile of lenadogene nolparvovec gene therapy in MT-ND4 LHON treated patients [11][12][13].…”
Section: Discussion
supporting
confidence: 79%
Absence of lenadogene nolparvovec DNA in a brain tumor biopsy from a patient in the REVERSE clinical study, a case report
BMC Neurol
Self Cite
Abstract
Smart CitationsHow the paper below cites the one you are viewing
“…The mean BCVA of treated subjects remained clearly on-chart, contrary to the natural history of the disease reported in MT-ND4 patients aged 15 and over at onset ( 3 ). Importantly, the continuous improvement of BCVA was reported in both eyes of unilaterally treated subjects, confirming the contralateral treatment effect of lenadogene nolparvovec reported at earlier time points in the RESCUE and REVERSE trials ( 10 , 11 ). Indeed, the absolute difference in change from baseline between drug-treated and sham-treated eyes was similar 2 and 3 years after treatment administration.…”
Section: Discussion
supporting
confidence: 79%
“…Because all MT-ND4 subjects were treated with lenadogene nolparvovec, an intrapatient comparison before and after treatment was used to assess the impact of treatment on quality of life, highlighting daily benefits experienced by each treated patient. In the overall REVERSE and RESCUE population, most of the quality-of-life metrics showed a clinically meaningful improvement from baseline to week 96, consistent with reported improvement of the visual acuity (10,11). Similarly at 3 years after treatment, this clinically meaningful improvement of most metrics was maintained, consistent with the persistence of the treatment effect of lenadogene nolparvovec on BCVA.…”
Section: Discussion
supporting
confidence: 74%
Long-Term Follow-Up After Unilateral Intravitreal Gene Therapy for Leber Hereditary Optic Neuropathy: The RESTORE Study
Journal of Neuro-Ophthalmology
Self Cite
Abstract
Smart CitationsHow the paper below cites the one you are viewing
“…Thus, we demonstrate that the iRECs can rescue the ischemic eye, restoring normal retinal vascularization. Interestingly, we found that iRECs were able to migrate to the contralateral eye, undergoing a bilateral transfer previously reported in a gene therapy study 86 . This further displays the therapeutic capabilities of the iRECs, as they can transport to ischemic regions outside the injection site to help rescue the tissue.…”
Section: Discussion
supporting
confidence: 74%
Abstract